Celltrion, Inc. (KRX: 068270)

Market Cap	38.22T
Revenue (ttm)	2.88T
Net Income (ttm)	187.10B
Shares Out	212.12M
EPS (ttm)	933.64
PE Ratio	193.01
Forward PE	45.97
Dividend	714.29 (0.40%)
Ex-Dividend Date	Dec 27, 2024

Volume	208,187
Average Volume	461,786
Open	182,900
Previous Close	180,200
Day's Range	179,300 - 184,000
52-Week Range	160,300 - 211,000
Beta	0.11
RSI	48.58
Earnings Date	Feb 20, 2025

About Celltrion

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,391
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 068270

Financial Performance

In 2023, Celltrion's revenue was 2.18 trillion, a decrease of -4.71% compared to the previous year's 2.28 trillion. Earnings were 535.65 billion, a decrease of -0.41%.